drugset / Trial / NCT02970500
Effect of Methylphenidate on Cancer-related Cognitive Impairment
Phase 2
Terminated
20 enrolled
CHU de Quebec-Universite Laval
Fondation de l'Hôtel-Dieu de Lévis · collabPurdue Pharma LP · collabÉquipe de Recherche Michel-Sarrazin en Oncologie psychosociale et Soins palliatifs · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Cancer-related cognitive Impairment (CRCI), commonly referred to as "chemo brain" or "brain fog"-impact severely on the Quality of Life (QoL) of cancer survivors. However, it still remains underdiagnosed and challenging to treat. One of the treatment options is the use of psychostimulants such as Methylphenidate (MP), but well-designed clinical trials to test its efficacy are limited. We will conduct a phase II study with a mixed method design to explore the preliminary efficacy of MP to improve cognitive function and QoL in breast cancer patients after treatment with chemotherapy and/or radiotherapy and determine the parameters needed for designing a phase III study.
Timeline
- Start
- 2017-10-09
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methylphenidate | Small molecule | 20 mg | — |